ANNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Annexon Inc (ANNX) is not a strong buy at the moment for a beginner investor with a long-term focus. While there are potential catalysts in the pipeline and positive analyst ratings, the technical indicators are weak, financial performance is negative, and there is no significant recent news or trading activity to suggest immediate upside. It is better to monitor the stock for further developments or a stronger entry point.
The MACD histogram is negative (-0.195) and expanding downward, indicating a bearish trend. RSI is at 20.837, suggesting the stock is approaching oversold territory but not providing a clear signal. Moving averages are converging, showing no strong directional trend. Key support is at 5.247, and the stock is trading near this level, with resistance at 6.584.
Analysts have given positive ratings with high price targets, citing the commercial potential of Annexon's drug pipeline, particularly vonaprument in geographic atrophy and tanruprubart in Guillain-Barre syndrome. There is also asymmetric risk/reward potential highlighted by Wells Fargo.
The MACD and RSI indicate bearish momentum, and there is no recent news or significant insider or hedge fund activity to drive the stock.
In Q3 2025, Annexon reported no revenue growth (0% YoY), a net income loss of -$54.92M (though improved by 57.71% YoY), and an EPS of -0.37 (up 48% YoY). Gross margin remains 0%.
Analysts have a positive outlook, with Chardan giving a Buy rating and a $16 price target, Wells Fargo raising the price target to $27 citing increased probability of success in clinical trials, and BofA maintaining a Buy rating despite lowering the price target to $8.
